JP2004511426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004511426A5 JP2004511426A5 JP2001579774A JP2001579774A JP2004511426A5 JP 2004511426 A5 JP2004511426 A5 JP 2004511426A5 JP 2001579774 A JP2001579774 A JP 2001579774A JP 2001579774 A JP2001579774 A JP 2001579774A JP 2004511426 A5 JP2004511426 A5 JP 2004511426A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- zeta potential
- range
- kcl
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 239000002502 liposome Substances 0.000 claims description 30
- 125000002091 cationic group Chemical group 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 17
- 239000012216 imaging agent Substances 0.000 claims description 16
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 15
- 210000002244 magnetosome Anatomy 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000033115 angiogenesis Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- -1 cationic lipid Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 239000002872 contrast media Substances 0.000 claims description 4
- 239000004530 micro-emulsion Substances 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229930013356 epothilone Natural products 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- 125000005313 fatty acid group Chemical group 0.000 claims 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- XAWCMDFDFNRKGK-FQEVSTJZSA-N 1-O-palmityl-2-O-methyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCOC[C@H](CO)OC XAWCMDFDFNRKGK-FQEVSTJZSA-N 0.000 claims 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- DGPBVJWCIDNDPN-UHFFFAOYSA-N 2-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=CC=C1C=O DGPBVJWCIDNDPN-UHFFFAOYSA-N 0.000 claims 1
- 229960005536 Alkyl-lysophospholipid Drugs 0.000 claims 1
- 101100180240 Burkholderia pseudomallei (strain K96243) ispH2 gene Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 229940039231 contrast media Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000002961 echo contrast media Substances 0.000 claims 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 208000013210 hematogenous Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229910021432 inorganic complex Inorganic materials 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 101150017044 ispH gene Proteins 0.000 claims 1
- 239000000696 magnetic material Substances 0.000 claims 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 claims 1
- 229960003775 miltefosine Drugs 0.000 claims 1
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 claims 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims 1
- ZBNJXSZNWZUYCI-UHFFFAOYSA-N octadecyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C ZBNJXSZNWZUYCI-UHFFFAOYSA-N 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 11
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000013980 iron oxide Nutrition 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000005639 Lauric acid Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 238000012632 fluorescent imaging Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000010441 alabaster Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000012438 extruded product Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical class O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002777 nucleoside Chemical class 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20167300P | 2000-05-03 | 2000-05-03 | |
| PCT/IB2001/001206 WO2001082899A2 (en) | 2000-05-03 | 2001-05-03 | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004511426A JP2004511426A (ja) | 2004-04-15 |
| JP2004511426A5 true JP2004511426A5 (https=) | 2005-02-03 |
Family
ID=22746804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001579774A Pending JP2004511426A (ja) | 2000-05-03 | 2001-05-03 | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20020034537A1 (https=) |
| EP (1) | EP1278512A2 (https=) |
| JP (1) | JP2004511426A (https=) |
| AU (2) | AU6627201A (https=) |
| CA (1) | CA2406650C (https=) |
| CZ (1) | CZ20023913A3 (https=) |
| HU (1) | HUP0301835A2 (https=) |
| MX (1) | MXPA02010801A (https=) |
| PL (1) | PL366025A1 (https=) |
| WO (1) | WO2001082899A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12617847B2 (en) | 2010-11-30 | 2026-05-05 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| AU2001253041A1 (en) * | 2000-03-31 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Dendrimer composition for magnetic resonance analysis |
| US6551344B2 (en) * | 2000-04-26 | 2003-04-22 | Ev3 Inc. | Septal defect occluder |
| EP1530465B2 (en) * | 2002-06-26 | 2015-12-16 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| EP1553924B1 (en) * | 2002-06-26 | 2010-12-08 | MediGene AG | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| PT2286795T (pt) * | 2002-06-26 | 2017-01-27 | Syncore Biotechnology Co Ltd | Processo de produção de uma preparação lipossomal catiónica que compreende um composto lipófilo |
| EP1374864A1 (en) * | 2002-06-26 | 2004-01-02 | Munich Biotech AG | Amphiphilic taxane compositions |
| US20040024317A1 (en) * | 2002-07-31 | 2004-02-05 | Uzgiris Egidijus E. | Method for assessing capillary permeability |
| AU2003287250B9 (en) * | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| ES2431520T3 (es) * | 2003-01-25 | 2013-11-26 | Seno Medical Instruments, Inc. | Procedimiento de formación de imágenes optoacústicas de contraste elevado utilizando nanopartículas no esféricas |
| FR2855315B1 (fr) * | 2003-05-23 | 2005-08-19 | Centre Nat Rech Scient | Ferrofluides stables en milieu neutre et ferrofluides modifies obtenus par modification de la surface des particules de ces ferrofluides |
| US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| US20080019918A1 (en) * | 2004-09-10 | 2008-01-24 | Takao Aoki | Medicinal Preparation |
| JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP1896007B1 (en) | 2005-05-04 | 2014-03-19 | Medigene AG | Method of administering a cationic liposomal preparation comprising paclitexel |
| JP5478886B2 (ja) * | 2005-10-20 | 2014-04-23 | ジョージタウン・ユニバーシティ | 癌の早期ｍｒｉ検出を改善するための腫瘍標的化ナノ送達系 |
| BRPI0709075A2 (pt) | 2006-03-20 | 2011-10-11 | Medigene Ag | tratamento de cáncer de mama triplo receptor negativo |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP3173068B1 (en) * | 2006-05-02 | 2020-09-09 | University of Miami | Topical co-enzyme q10 formulations and treatment of wounds |
| WO2007133801A2 (en) * | 2006-05-15 | 2007-11-22 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
| WO2007134819A1 (en) * | 2006-05-18 | 2007-11-29 | Medigene Ag | Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| WO2008045976A2 (en) * | 2006-10-10 | 2008-04-17 | Squicor | Compositions and methods for treating and diagnosing cancers |
| US20110002851A1 (en) * | 2006-11-03 | 2011-01-06 | Medigene Ag | Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| TW201634479A (zh) | 2007-12-05 | 2016-10-01 | 中外製藥股份有限公司 | 抗ｎｒ１０抗體及其應用 |
| RU2496482C2 (ru) | 2008-03-05 | 2013-10-27 | Бакстер Интернэшнл Инк. | Композиции и способы для доставки лекарственных средств |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US8329161B2 (en) * | 2008-05-01 | 2012-12-11 | National Health Research Institutes | Red blood cell-derived vesicles as a nanoparticle drug delivery system |
| JP5596027B2 (ja) | 2008-06-18 | 2014-09-24 | レイセオン カンパニー | カテーテル |
| WO2010014792A2 (en) | 2008-07-30 | 2010-02-04 | Sterling Lc | Method and device for incremental wavelength variation to analyze tissue |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010053916A2 (en) * | 2008-11-04 | 2010-05-14 | Sterling Lc | Method and device for wavelength shifted imaging |
| US20100135912A1 (en) * | 2008-12-02 | 2010-06-03 | Gambhir Sanjiv S | Magnetotactic bacteria mri positive contrast enhancement agent and methods of use |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| DE102009031274A1 (de) * | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| US9144664B2 (en) | 2009-10-01 | 2015-09-29 | Sarcos Lc | Method and apparatus for manipulating movement of a micro-catheter |
| US8717428B2 (en) * | 2009-10-01 | 2014-05-06 | Raytheon Company | Light diffusion apparatus |
| US8828028B2 (en) | 2009-11-03 | 2014-09-09 | Raytheon Company | Suture device and method for closing a planar opening |
| CN102811726B (zh) * | 2009-11-18 | 2015-03-18 | 纳米细菌公司 | 通过由提取自趋磁细菌并经受交变磁场的磁小体的各种链所产生的热的释放诱导的癌症或肿瘤的治疗 |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US10842770B2 (en) | 2010-05-03 | 2020-11-24 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| TWI452136B (zh) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| US10029115B2 (en) * | 2011-04-08 | 2018-07-24 | Sanovas Intellectual Property, Llc | Photodynamic therapy for tumors with localized delivery |
| CN102419370B (zh) * | 2011-08-04 | 2014-08-27 | 武汉理工大学 | 用于检测小鼠组织内Bt杀虫蛋白的免疫磁小体及其制备方法 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US10379026B2 (en) | 2012-08-29 | 2019-08-13 | Inguran, Llc | Cell processing using magnetic particles |
| NZ734393A (en) | 2012-08-29 | 2020-02-28 | Inguran Llc | Magnetic removal or identification of damaged or compromised cells or cellular structures |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| KR101860117B1 (ko) | 2013-12-13 | 2018-05-21 | 유겐가이샤 머큐리 에셋 매니지먼트 | 관절 연골 이미징 조성물 |
| US9775842B2 (en) | 2014-03-14 | 2017-10-03 | Rhode Island Hospital | Nanocarriers and their processing for diagnostics and therapeutics |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| CR20180554A (es) | 2016-04-28 | 2019-01-10 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用 |
| CN110461358A (zh) | 2017-03-31 | 2019-11-15 | 公立大学法人奈良县立医科大学 | 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| ES3017696T3 (en) | 2017-05-17 | 2025-05-13 | Bpgbio Inc | Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa |
| CN119161488A (zh) | 2017-11-01 | 2024-12-20 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
| CN108751397A (zh) * | 2018-05-31 | 2018-11-06 | 北京北华中清环境工程技术有限公司 | 添加功能化磁性微球利用mbr进行煤制气废水处理的方法 |
| WO2021221167A1 (ja) * | 2020-04-30 | 2021-11-04 | 国立大学法人 長崎大学 | ガン治療薬及びガン治療方法 |
| CN112754996B (zh) * | 2021-03-16 | 2023-03-31 | 江西省科学院生物资源研究所 | 一种鱼精蛋白短肽修饰的紫杉醇脂质体及其制备方法 |
| US20250235564A1 (en) * | 2021-10-11 | 2025-07-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Composite ink formulations for endoscopic imaging |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635180A (en) * | 1988-02-17 | 1997-06-03 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| US5230883A (en) * | 1989-05-04 | 1993-07-27 | Wisconsin Alumni Research Foundation | Method for localization and treatment of tumors using polylysine complexes |
| US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
| DE4428851C2 (de) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie |
| US5908635A (en) * | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| GB9416884D0 (en) * | 1994-08-20 | 1994-10-12 | Danbiosyst Uk | Drug delivery compositions |
| RU2147243C1 (ru) * | 1994-09-27 | 2000-04-10 | Нюкомед Имагинг А/С | Контрастное средство |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| DE19912502A1 (de) * | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
| KR100591767B1 (ko) * | 1999-09-09 | 2006-06-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀 |
-
2001
- 2001-05-03 PL PL01366025A patent/PL366025A1/xx not_active Application Discontinuation
- 2001-05-03 AU AU6627201A patent/AU6627201A/xx active Pending
- 2001-05-03 AU AU2001266272A patent/AU2001266272B2/en not_active Ceased
- 2001-05-03 CA CA002406650A patent/CA2406650C/en not_active Expired - Fee Related
- 2001-05-03 CZ CZ20023913A patent/CZ20023913A3/cs unknown
- 2001-05-03 US US09/847,538 patent/US20020034537A1/en not_active Abandoned
- 2001-05-03 HU HU0301835A patent/HUP0301835A2/hu unknown
- 2001-05-03 EP EP01943744A patent/EP1278512A2/en not_active Withdrawn
- 2001-05-03 JP JP2001579774A patent/JP2004511426A/ja active Pending
- 2001-05-03 MX MXPA02010801A patent/MXPA02010801A/es active IP Right Grant
- 2001-05-03 WO PCT/IB2001/001206 patent/WO2001082899A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12617847B2 (en) | 2010-11-30 | 2026-05-05 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004511426A5 (https=) | ||
| Lakkadwala et al. | Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma | |
| DK2670394T3 (en) | NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND APPLICATIONS THEREOF | |
| AU2001266272B2 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
| JP2021147316A (ja) | センチネルリンパ節イメージング剤 | |
| AU2001266272A1 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
| CN1089470A (zh) | 用于核磁共振成像的颗粒及其制备方法 | |
| CN101123996A (zh) | 用于增强成像对比度的组合物和方法 | |
| WO2022122054A1 (zh) | 提高阿霉素肿瘤主动靶向性和肾脏保护的纳米结构脂质制剂及制备方法 | |
| JP2003530362A (ja) | 診断剤をターゲッティングするための脂質ベースの系 | |
| KR20150078952A (ko) | 활성 성분 및 조영제를 포함하는 리포좀 및 그의 용도 | |
| CN104490786B (zh) | 一种靶向多功能双载药脂质体的制备方法和应用 | |
| CN103446588B (zh) | 靶向型诊疗联用药物及其制备方法和应用 | |
| CN110433296A (zh) | 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用 | |
| US6479033B1 (en) | Antitumor cystostatic and contrast agent | |
| CN113307824B (zh) | 一种双亲性材料及其在制备脂质体中的应用 | |
| PT115474B (pt) | Nanossistema magnético e método para produzir o nanossistema | |
| US20210346524A1 (en) | Fusogenic liposomes for selective imaging of tumor cells | |
| JP6903318B2 (ja) | 一酸化窒素内包バブルリポソーム及びその利用 | |
| JP5463548B2 (ja) | 超音波治療用リポソーム及び超音波治療促進用リポソーム | |
| US20250352575A1 (en) | Manufacturing and application of manganese-based theranostic nanoparticle technology | |
| JP2014503582A (ja) | 親水性プロドラッグの局所放出用担体 | |
| ES2702561T3 (es) | Sistemas de aporte de nanopartículas, preparación y usos de los mismos | |
| Mady et al. | Enhanced Ehrlich tumor inhibition using DOX-NP™ and gold nanoparticles loaded liposomes | |
| ES2579912B1 (es) | Composiciones que contienen liposomas, ácidos grasos poliinsaturados omega-3 de cadena larga y nanopartículas superparamagnéticas y su uso en el tratamiento de tumores malignos |